Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Pharmacologic Substance > Immunomodulatory IMiD Drugs

Immunomodulatory IMiD Drugs

Immunomodulatory IMiD Drugs are a class of medications that exert their effects by modulating the immune system.
These drugs are used to treat various conditions, including cancer, autoimmune disorders, and inflammatory diseases.
PubCompare.ai's AI-driven platform can help optimize your research protocols and enhance reproducibility for Immunomodulatory IMiD Drugs.
The platform uses AI-driven comparisons to identify the most effective products by locating the best protocols from literature, pre-prints, and patents.
Streamline your research and get better results with PubCompare.ai's innovative solution.

Most cited protocols related to «Immunomodulatory IMiD Drugs»

1
Newly Diagnosed Multiple Myeloma Patients
Cited 64 times
A total of 4445 NDMM patients were enrolled in 11 international, multicentre clinical trials, from 2005 to 2012 (Table S2). The results of these trials were previously reported (clinicaltrials.gov: NCT01346787, NCTC00551928, NCT01091831, NCT01093196, NCT01190787, NCT01063179, NCT01134484, NCT00461747, NCT00200681; Eudract: 2005-004714-32; Netherlands Trial Register: NTR213).14 (link)–24 (link) Patients gave written informed consent before entering the source trials, which were performed in accordance with the Declaration of Helsinki.
All patients received new drugs [immunomodulatory agents (IMIDs) or proteasome inhibitors (PIs)] in association with conventional chemotherapy as upfront treatment or incorporated into pre-transplant induction or post-transplant maintenance strategies, except for the patients enrolled in IFM 2005-01 trial who were randomized to vincristine-adriamicyn-dexamethasone (VAD) induction and VAD-dexamethasone-cyclophosfamide-etoposide-cisplatin before ASCT (Table S3). Baseline data collected included: age, gender, ISS stage, CA detected by iFISH and serum LDH level. Data about ISS stage, CA by FISH and serum LDH were simultaneously available in 3060/4445 patients. The primary endpoint was OS, defined as the time from start of treatment until death due to any cause, or until the last date the patient was known to be alive. The secondary endpoint was progression-free survival (PFS), defined as the time from start of treatment until progression or death due to any cause, or until the last date the patient was known to be progression-free.
Palumbo A., Avet-Loiseau H., Oliva S., Lokhorst H.M., Goldschmidt H., Rosinol L., Richardson P., Caltagirone S., Lahuerta J.J., Facon T., Bringhen S., Gay F., Attal M., Passera R., Spencer A., Offidani M., Kumar S., Musto P., Lonial S., Petrucci M.T., Orlowski R.Z., Zamagni E., Morgan G., Dimopoulos M.A., Durie B.G., Anderson K.C., Sonneveld P., San Miguel J., Cavo M., Rajkumar S.V, & Moreau P. (2015). Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of Clinical Oncology, 33(26), 2863-2869.
Publication 2015
Dexamethasone Disease Progression Fishes Gender Grafts Immunomodulating Agents Immunomodulatory IMiD Drugs Patients PE regimen Pharmaceutical Preparations Pharmacotherapy Proteasome Inhibitor Serum Vincristine
2
Prognostic Impact of Risk Stratification in Multiple Myeloma
Cited 12 times
An explorative analysis of the 3060 patients for whom ISS, CA and LDH data were simultaneously available was conducted. The K-adaptive partitioning,25 dedicated to censored survival data (minimax-based partitioning rule by log-rank test), was used for ISS/CA/LDH grouping: this routine gave an optimal number of three subgroups: the R-ISS I, II and III. The OS and PFS curves were estimated by the Kaplan-Meier method and compared by the log-rank test. OS and PFS were then analyzed through the Cox proportional hazards model, comparing the following risk factors by the Wald test: age at diagnosis (≤65 vs >65 years), gender (male vs female), iFISH (high-risk vs standard-risk CA), LDH (high vs normal), ISS (II vs I and III vs I) and R-ISS grouping as defined by the recursive partitioning procedure. The effects of the baseline features (age, gender and R-ISS) were also assessed by the multivariate Cox model; as in the univariate analysis, the R-ISS stage was treated as time-dependent variable. Subgroup analyses of PFS and OS were performed to confirm the effect of R-ISS in different subgroups of patients, that is in patients older and younger than 65 years of age, and in patients receiving ASCT or not, those receiving PI or not and those receiving IMIDs or not. Patients characteristics were tested using the Fisher’ exact test for categorical variables and the Mann-Whitney test for continuous ones. All reported p-values were two-sided, at the conventional 5% significance level. Data were analyzed as of December 2014 by R 3.0.1 package kaps and IBM SPSS 21.0.0.
Palumbo A., Avet-Loiseau H., Oliva S., Lokhorst H.M., Goldschmidt H., Rosinol L., Richardson P., Caltagirone S., Lahuerta J.J., Facon T., Bringhen S., Gay F., Attal M., Passera R., Spencer A., Offidani M., Kumar S., Musto P., Lonial S., Petrucci M.T., Orlowski R.Z., Zamagni E., Morgan G., Dimopoulos M.A., Durie B.G., Anderson K.C., Sonneveld P., San Miguel J., Cavo M., Rajkumar S.V, & Moreau P. (2015). Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of Clinical Oncology, 33(26), 2863-2869.
Publication 2015
Acclimatization Diagnosis Gender Immunomodulatory IMiD Drugs Males Patients Woman Youth
3
Gut Microbiome Profiles in Immune-Mediated Diseases
Cited 3 times
The study cohort is described in Table 1. For our disease cohorts, we chose patients with CD, UC, MS, and RA, since these diseases are all T cell-mediated yet preferentially target distinct organs. Moreover, previous studies have reported significantly increased odds of developing MS or RA in the presence of IBD [10 (link)] suggestive of a common etiological component. Research and ethics approval was obtained from the University of Manitoba’s Research Ethics Board. Patients with an IMID were recruited between 2010 and 2012 from the IBD Clinical and Research Centre and the Rheumatology ambulatory care clinic, both located at the Health Sciences Centre, Winnipeg, Canada. IMID patients were included if they met the standard criteria for case definition, i.e., Montreal Classification for IBD [17 ], 2010 McDonald criteria for MS [18 (link)], and 2010 American College of Rheumatology classification criteria for RA [19 (link)]; were over 18 years of age; and had not taken antibiotics in the previous 8 weeks. HC were recruited at the University of Manitoba Health Sciences Centre. For our HC cohort, we enrolled adults who had not taken antibiotics in the previous 8 weeks and had no medical history of gastrointestinal, neurological, or joint disease. Each participant self-collected two stool specimens approximately 2 months apart. The stool samples were kept refrigerated at 4 °C until transport. The stool was transported to the laboratory on ice and stored at − 80 °C until processing.

Patient data at time of sample procurement

DiseaseAverage age, yearsaN (female/male)a
Crohn’s disease49.920 (14/5)
Ulcerative colitis51.219 (11/8)
Multiple sclerosis47.319 (14/4)
Rheumatoid arthritis62.321 (14/7)
Healthy controls32.423 (12/11)

aTabulated metadata does not include information from patients whose metadata was not available

Forbes J.D., Chen C.Y., Knox N.C., Marrie R.A., El-Gabalawy H., de Kievit T., Alfa M., Bernstein C.N, & Van Domselaar G. (2018). A comparative study of the gut microbiota in immune-mediated inflammatory diseases—does a common dysbiosis exist?. Microbiome, 6, 221.
Full text: Click here
Publication 2018
Adult Antibiotics Arthropathy Care, Ambulatory Feces Immunomodulatory IMiD Drugs Males Patients Specimen Collection T-Lymphocyte Ulcer Woman
4
Profiling Newly Diagnosed, Treatment-Naive Multiple Myeloma
Cited 3 times
The design of the study is to prospectively profile newly diagnosed, treatment naive MM from 1000 patients with longitudinal clinical follow up. Tumor specimens collected at diagnosis and relapse are interrogated by whole-exome, modified low pass whole-genome, and or RNA sequencing. The longitudinal component requires clinical follow-up of each patient with collection of clinical parameters four times annually over a period of 10 years. Furthermore, each patient participating into the study underwent an IMID and/or Proteasome inhibitor based treatment regimen at diagnosis determined by the treating oncologist.
CoMMpass data are systematically analyzed and periodically released in the form of Interim Analyses on a biannual basis. Interim Analysis 9 (IA9) is comprised of 796 unique baseline newly diagnosed bone-marrow samples with high quality WES data of which, 75 have confirmed progression with comprehensive clinical annotation. In addition, IA9 is comprised of 520 bone marrow baseline samples that were analyzed by both whole-exome and RNAseq platforms. The data is publically available at dbGAP accession number phs000748.
In this study, we performed our analysis on whole-exome data from 741 of treatment-naïve bone marrow derived MM matched normal samples from IA9, from those cases who self-reported race as either African American or Caucasian. To ensure high quality WES data for downstream copy number analysis, we removed samples that had maximum segmentation count above 2,500 to be in concordance with GISTIC 2.0 recommendation of maximum segment counts [22 (link)]. This resulted in final 721 samples that passed the quality threshold and were used to determine genetic ancestry across the samples.
Manojlovic Z., Christofferson A., Liang W.S., Aldrich J., Washington M., Wong S., Rohrer D., Jewell S., Kittles R.A., Derome M., Auclair D., Craig D.W., Keats J, & Carpten J.D. (2017). Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases. PLoS Genetics, 13(11), e1007087.
Full text: Click here
Publication 2017
Birth Bone Marrow Caucasoid Races Exome Genome Immunomodulatory IMiD Drugs Negroes Neoplasms Oncologists Patients Proteasome Inhibitor Relapse Treatment Protocols
5
Comprehensive Mutation Profiling in Multiple Myeloma
Cited 3 times
We established a MM-specific 47 gene mutation panel [9 ] including a selection of 39 genes expressed in MM (by analyzing gene expression profiling public datasets) with nonsynonymous mutations found in ≥3 % of published MM genomes [6 (link), 10 (link)]. To this, we added eight genes targeted by the most commonly used MM therapies, associated with resistance to IMiDs (CRBN, CUL4A, CUL4B, DDB1, and IRF4), proteasome inhibitors (PSMG2, PSMB5) and glucocorticoid therapies (NR3C1) (Table 1). We employed the Ion Torrent semiconductor sequencing platform (PGM, Life Technologies, Carlsbad, CA, USA), using 20 ng of starting DNA for each sample (10 ng per primer pool). The coding regions of the 47 genes were amplified in 200-bp libraries using customized oligos (Ion AmpliSeq Designer, Life Technologies). Overall, 2875 amplicons, covering 96 % of the M3P exons, were analyzed per sample, multiplexed in two library preparations (Ion AmpliSeq Library Kit 2.0, Life Technologies). Template preparation and enrichment of DNA libraries was done on the Ion OneTouch2 and Ion OneTouch ES (Life Technologies) automated system, respectively. Batches of four samples were barcoded (Ion Xpress Barcode Adapters, Life Technologies), pooled, and sequenced using Ion 318 and 318v2 chips and the Ion Sequencing 200 Kit v2 (Life Technologies). Sequencing data were analyzed using the Ion Reporter Software v1.6 (protocols applied: “TumorNormalTemplate 1.6.2” and “Ion QC protocol”, Life Technologies, Carlsbad, CA, USA), visualized, and manually reviewed using the Integrative Genomics Viewer (IGV, Broad Institute, Cambridge, MA, USA). Variants were analyzed using SIFT, Provean (J. Craig Venter Institute) [11 (link), 12 (link)], PolyPhen-2 (Harvard University) [13 (link)], and the Catalogue of Somatic Mutations in Cancer (COSMIC, Welcome Trust Sanger Institute, UK) [14 (link)]. Mutation calls were considered positive when called by ≥10 % variant reads and >20 times sequencing coverage depth in the tumor sample. In already characterized cancer-related mutations (COSMIC database), the threshold was reduced to 3 %. We additionally considered mutations called below threshold if a matching variant above the threshold was found in the corresponding tumor sample.
Kortüm K., Langer C., Monge J., Bruins L., Zhu Y., Shi C., Jedlowski P., Egan J., Ojha J., Bullinger L., Kull M., Ahmann G., Rasche L., Knop S., Fonseca R., Einsele H., Stewart A, & Braggio E. (2015). Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M3P). Annals of hematology, 94(7), 1205-1211.
Publication 2015
2',5'-oligoadenylate cereblon protein, human Cosmic composite resin DDB1 protein, human Diploid Cell DNA Chips DNA Library Exons Genes Genes, vif Genome Glucocorticoids Immunomodulatory IMiD Drugs interferon regulatory factor 4, human Malignant Neoplasms Mutation Neoplasms Oligonucleotide Primers Proteasome Inhibitor PSMB5 protein, human

Most recents protocols related to «Immunomodulatory IMiD Drugs»

1
Daratumumab Therapy for Relapsed/Refractory MM
We retrospectively reviewed the medical records of patients diagnosed with MM according to the International Myeloma Working Group (IMWG) guidelines [15 (link)] at 10 medical centers in South Korea between December 2004 and June 2021. The inclusion criteria were as follows: (1) patients treated with daratumumab after more than three lines of therapy administered previously, including PI, IMiD, and/or ASCT, and (2) patients who received at least two cycles of daratumumab (total eight infusions) and underwent complete blood count (CBC) evaluation before and after daratumumab infusion. The exclusion criteria were as follows: (1) patients who received concurrent administration of other antimyeloma therapy with daratumumab and (2) patients with missing CBC values or whose treatment response was not assessed. This study was approved by the Institutional Review Board of Kyungpook National University Hospital (IRB no. 2021-05-13) and by each participating center in accordance with the Declaration of Helsinki. Written informed consent by the patients was waived due to a retrospective nature of our study.
Cho H.J., Jo J.C., Lee Y.J., Lee M.W., Kim D.Y., Shin H.J., Im S.N., Lee J.H., Bae S.H., Do Y.R., Lee W.S., Kim M.K., Jung J., Lee J.M., Kim J.H., Baek D.W., Sohn S.K, & Moon J.H. (2023). Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma. The Korean Journal of Internal Medicine, 38(2), 238-247.
Publication 2023
daratumumab Immunomodulatory IMiD Drugs Multiple Myeloma Patients
2
SARS-CoV-2 Antibody Response in IMID Patients
The eligibility criteria and SARS-CoV-2 IgG assay evaluation have been previously reported.6 (link) Serum SARS-CoV-2 IgG detection and titres against the S1/2 proteins were measured at baseline, 3–4 weeks post first vaccination and 4 weeks post second vaccination. Participants with IMID were randomised to continue or withhold their DMARD in each of the vaccine groups following the first dose only and the same intervention was then applied following the third (booster) dose.6 (link) To summarise, in participants on weekly methotrexate, the vaccination was timed on the day the dose was due however the methotrexate dose was paused on the day of vaccination for two cycles. Participants on daily DMARDs withheld therapy for 1 week starting on the day of first vaccination. For those on bDMARDs, therapy was delayed by 1 week following their usual injection cycle (eg, for bDMARD administered every 2 weeks, the vaccination was timed at the end of the 2 weeks and then restarted 1 week later leaving an interval of 3 weeks). Participants who contracted COVID-19 infection prior to the third vaccine were excluded in the analysis. The participants were stratified according to the vaccine received and intervention group allocated during the first two vaccinations (table 1). The drugs used in each of the DMARD classes are listed in online supplemental table 1.
Statistical analyses and graphs were performed using either STATA 17.0 (StataCorp) or RStudio. Fisher’s exact test was used to compare seroconversion rates between the various DMARD and control groups while the Wilcoxon-Mann-Whitney U test was used to compare antibody titres between the groups. We conducted univariate logistic regression to assess predictive factors for developing protective SARS-CoV2 IgG antibody titre levels. Multivariate logistic regression was then performed to generate adjusted estimates for factors, which were found to be significant on univariate analysis.
We conducted simple linear regression using log-transformed IgG titre levels as the outcome variable and time since second vaccine dose administration as the explanatory variable to investigate the rate of antibody decay among the cohort studied.
Tran A.P., Tassone D.F., Ding N.S, & Nossent J. (2023). Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2). RMD Open, 9(1), e002871.
Publication 2023
Antirheumatic Drugs, Disease-Modifying Biological Assay COVID-19 Vaccines COVID 19 Eligibility Determination Immunoglobulin G Immunoglobulins Immunomodulatory IMiD Drugs Infection Methotrexate Pharmaceutical Preparations Proteins SARS-CoV-2 Secondary Immunization Serum Severe Acute Respiratory Syndrome Therapeutics Vaccination Vaccines
3
Docking Predictions of IMiDs on Cereblon
Assessments of prospective docking pockets and docking predictions for S enantiomeric forms of TFBP, TFNBP and thalidomide-like drugs on the structure of cereblon were investigated using automated software [49 (link)]. This was followed by a cavity-based blind drug docking prediction utility [50 (link)] to appraise the characteristics of the computed drug docking predictions of these IMiDs. The drug docking pockets and the binding differences between TFBP, TFNBP, thalidomide and pomalidomide in cereblon were determined for the best scoring attributes of these chemical agents. In short, the crystal structure of human cereblon in complex with DDB1 and lenalidomide (4TZ4: https://www.rcsb.org/structure/4TZ4) was downloaded in PDB format from the PDB database. The chain C (human cereblon) was separated from the remainder of the crystal structure complex and was utilized in docking predictions for the S enantiomeric forms of the study compounds. The S enantiomer was chosen as former x-ray crystallographic studies have reported that this enantiomer of thalidomide-like IMiDs better binds cereblon [51 (link)], notwithstanding that molecular modelling computational data does not necessarily simulate or fall in line with all experimental data from prior x-ray crystallographic studies [52 (link)]. Playmolecule, an automated server that employs a software DeepSite [48 (link), 49 (link)] to establish the core binding sites, was used to simulate potential interactions between TFBP, TFNBP or thalidomide-like compounds with human cereblon. An automated docking software [53 (link)] was used to investigate potential similarities and differences in the pharmacophore pocket engaged by the test drugs. Briefly, two files were uploaded that included the C-chain (human cereblon) of the PDB ID 4TZ4 without lenalidomide and damaged DNA binding protein 1 (DDB1) and the drugs individually in their PDB formats to the Docking server [53 (link)]. For docking pocket predictions, the results appear as the number of preferential pockets determined with their relevant scores. Results of docking were collected with individual Vina scores, cavity sizes, docking centers, poses and sizes of predicted cavities for the drugs noted above. The resulting drug-cereblon complexes were visualized using the drug discovery studio visualizer software BIOVIA [49 (link)].
Lecca D., Hsueh S.C., Luo W., Tweedie D., Kim D.S., Baig A.M., Vargesson N., Kim Y.K., Hwang I., Kim S., Hoffer B.J., Chiang Y.H, & Greig N.H. (2023). Novel, thalidomide-like, non-cereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury. Journal of Biomedical Science, 30, 16.
Full text: Click here
Publication 2023
Binding Sites chemical properties Cortodoxone Crystallography, X-Ray DDB1 protein, human Dental Caries DNA-Binding Proteins Homo sapiens Immunomodulatory IMiD Drugs Lenalidomide Pharmaceutical Preparations pomalidomide Thalidomide Visually Impaired Persons
4
Relapsed/Refractory Multiple Myeloma Treatment
All patients older than 18 years old with a relapse or a progression of previously diagnosed symptomatic MM according to International Myeloma Working Group (IMWG) criteria and who were previously treated with at least two lines of therapy including at least one proteasome inhibitor and at least one of the immunomodulatory imide drugs (IMiDs) were included. Patients were to have a measurable disease (M-protein and/or free light chains) in serum and/or urine.
Metselaar J., Lammers T., Boquoi A., Fenk R., Testaquadra F., Schemionek M., Kiessling F., Isfort S., Wilop S, & Crysandt M. (2023). A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma. Drug Delivery and Translational Research, 13(4), 915-923.
Full text: Click here
Publication 2023
Disease Progression Immunomodulatory IMiD Drugs Light M protein, multiple myeloma Multiple Myeloma Patients Proteasome Inhibitor Relapse Serum Therapeutics Urine
5
Synthesis and Characterization of Fluorinated Heterocyclic Compounds
Compounds 1a–c, (S)-1b [26 (link)], 1d–f, 3 [28 (link)], and 5 [32 (link)] were obtained as previously described. Other reagents are commercially available and were purchased from Alfa Aesar (Heysham, UK). Melting points were obtained on a SMP3 apparatus (Barloworld Scientific, Staffordshire, UK) and are uncorrected. Optical rotations were measured on a Perkin Elmer M341 polarimeter (Perkin Elmer, Waltham, MA, USA). The reactions were monitored by thin layer chromatography (TLC) using silica gel precoated Sorbfil plates (Imid, Krasnodar, Russia); compounds were visualized by UV irradiation at 254 nm and iodine vapors. Flash column chromatography was performed using Silica gel 60 (230–450 mesh) (Alfa Aesar, Heysham, UK). The 1H, 19F, and 13C NMR spectra were recorded on a Bruker AVANCE 500 spectrometer (Bruker, Karlsruhe, Germany). Chemical shifts are given in ppm and are referenced to TMS (or DSS) and hexafluorobenzene as internal standards and multiplicities are reported as s (singlet), d (doublet), t (triplet), and m (multiplet). The 1H and 19F NMR spectra of compounds 6 and 7 were recorded in DMSO-d6 at 100 °C; the 1H and 13C NMR spectra of compounds 2b,c were recorded in a D2O–NaOD mixture at ambient temperature. For NMR spectra of the compounds obtained, see the Supplementary Materials, Figures S1–S18. CHN-Elemental analysis was performed using Perkin Elmer 2400 II analyzer (Perkin Elmer, Waltham, MA, USA). High resolution mass spectra were obtained on a Bruker maXis Impact HD mass spectrometer (Bruker, Karlsruhe, Germany), electrospray ionization (ESI) with direct sample inlet (4 L/min flow rate). Analytical chiral HPLC of compounds (S)-9 and 9 was performed on an Agilent 1100 instrument (Agilent Technologies, Santa Clara, CA, USA) using a (S,S)-Whelk-O1 column (250 × 4.6 mm, 5 µm) (Phenomenex, Torrance, CA, USA); flow rate 0.8 mL/min, detection at 280 nm. For HPLC data for compounds (S)-9 and 9, see the Supplementary Materials, Figures S19 and S20.
Krasnov V.P., Vozdvizhenskaya O.A., Baryshnikova M.A., Pershina A.G., Musiyak V.V., Matveeva T.V., Nevskaya K.V., Brikunova O.Y., Gruzdev D.A, & Levit G.L. (2023). Synthesis and Cytotoxic Activity of the Derivatives of N-(Purin-6-yl)aminopolymethylene Carboxylic Acids and Related Compounds. Molecules, 28(4), 1853.
Full text: Click here
Publication 2023
Carbon-13 Magnetic Resonance Spectroscopy Chromatography hexafluorobenzene High-Performance Liquid Chromatographies Immunomodulatory IMiD Drugs Iodine Mass Spectrometry Optical Rotation Silica Gel Sulfoxide, Dimethyl Thin Layer Chromatography Triplets Ultraviolet Rays

Top products related to «Immunomodulatory IMiD Drugs»

1
Ods am by YMC
Sourced in United States
The YMC ODS-AM is a reverse-phase high-performance liquid chromatography (HPLC) column designed for analytical separations. It features an octadecyl (C18) stationary phase bonded to a silica support material. This column is intended for use in HPLC systems to separate and analyze a variety of organic compounds.
2
Maxis impact mass spectrometer by Bruker
Sourced in Germany, United States
The MaXis impact mass spectrometer is a high-resolution time-of-flight mass spectrometer designed for accurate mass measurements and high-throughput analysis. It features a high-performance ion optics system and a fast data acquisition system to provide precise mass determination and enhanced sensitivity.
3
Rid 20a refractometer by Shimadzu
Sourced in Japan
The Shimadzu RID-20A is a refractive index detector designed for high-performance liquid chromatography (HPLC) applications. It accurately measures the refractive index of eluted samples, providing a reliable method for detecting and quantifying analytes in liquid chromatography experiments.
4
Dpx 500 by Bruker
Sourced in Germany, United States
The DPX-500 is a nuclear magnetic resonance (NMR) spectrometer designed for analytical and research applications. It operates at a frequency of 500 MHz and is capable of performing a variety of NMR experiments to analyze the structure and properties of chemical compounds.
5
Perkin elmer 343 polarimeter by PerkinElmer
Sourced in United States
The Perkin-Elmer 343 polarimeter is a laboratory instrument designed to measure the optical rotation of a sample. It determines the angle of rotation of the plane of polarized light passing through a sample, which can provide information about the composition and concentration of chiral molecules in the sample.
6
Drx 700 by Bruker
Sourced in Germany
The DRX-700 is a high-performance nuclear magnetic resonance (NMR) spectrometer manufactured by Bruker. It is designed to provide researchers and scientists with a powerful tool for the structural analysis and characterization of chemical compounds.
7
Alphaplate by PerkinElmer
Sourced in United States
The AlphaPlate is a high-throughput cell-based assay platform designed for efficient and sensitive detection of biochemical and cell-based interactions. It utilizes the AlphaLISA and AlphaScreen technologies to measure a variety of analytes, including proteins, peptides, and small molecules, in a 96- or 384-well microplate format.
8
Anti dykddddk mouse mab by Fujifilm
Sourced in United States
The Anti-DYKDDDDK mouse mAb is a laboratory antibody used for detecting and purifying proteins that have been engineered to contain the DYKDDDDK peptide tag. The antibody specifically binds to this tag, allowing for the identification and isolation of the tagged proteins.
9
Envision plate reader by PerkinElmer
Sourced in United States, United Kingdom, Japan
The Envision plate reader is a multi-mode microplate reader designed for high-performance detection of fluorescence, luminescence, and absorbance signals in a wide range of microplate formats. It features advanced optics and detection technologies to enable precise and reliable data acquisition.
10
Lc 20 chromatograph by Shimadzu
Sourced in United States
The Shimadzu LC-20 is a high-performance liquid chromatograph designed for analytical and preparative separation and purification of chemical compounds. It features a precise solvent delivery system, a sensitive UV-Vis detector, and a robust column oven to ensure reliable and reproducible performance. The LC-20 is a versatile instrument suitable for a wide range of applications in various industries, including pharmaceuticals, environmental analysis, and food science.

More about "Immunomodulatory IMiD Drugs"

Immunomodulatory IMiD Drugs, also known as immunomodulatory drugs or IMiDs, are a class of medications that work by regulating the immune system.
These drugs are used to treat a variety of conditions, including cancer, autoimmune disorders, and inflammatory diseases.
The mechanism of action for Immunomodulatory IMiD Drugs involves modulating the activity of various immune cells, such as T cells, B cells, and natural killer cells.
This can lead to enhanced immune responses against diseased or abnormal cells, as well as reduced inflammation and autoimmune reactions.
Some common Immunomodulatory IMiD Drugs include lenalidomide, pomalidomide, and thalidomide.
These drugs have been studied extensively, with many published research protocols and findings available.
PubCompare.ai's innovative AI-driven platform can help optimize your research protocols and enhance reproducibility for Immunomodulatory IMiD Drugs by identifying the most effective products and protocols from the literature, preprints, and patents.
By using advanced AI-driven comparisons, PubCompare.ai's platform can streamline your research and help you achieve better results.
The platform's features include the ability to analyze data from various analytical techniques, such as mass spectrometry (e.g., YMC ODS-AM, MaXis impact mass spectrometer), refractometry (e.g., Shimadzu RID-20A refractometer), nuclear magnetic resonance (e.g., DPX-500, DRX-700), polarimetry (e.g., Perkin-Elmer 343 polarimeter), and fluorescence-based assays (e.g., AlphaPlate, Envision plate reader).
Additionally, the platform can integrate data from liquid chromatography (e.g., LC-20 chromatograph) to provide a comprehensive analysis of your research findings.
Streamlining your research and accessing the most effective protocols for Immunomodulatory IMiD Drugs can lead to more efficient and reproducible studies, ultimately advancing the understanding and treatment of various diseases.
Explore the capabilities of PubCompare.ai's AI-driven platform to optimize your research and get better results.